Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
193 results about "Anti vegf" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Anti–vascular endothelial growth factor therapy. Anti–vascular endothelial growth factor therapy, also known as anti-VEGF therapy or anti-VEGF medication, is the use of medications that block vascular endothelial growth factor. This is done in the treatment of certain cancers and in age-related macular degeneration.
Treatment with anti-VEGF antibodies
InactiveUS20050186208A1Effective approachExtended durationBiocidePeptide/protein ingredientsAbnormal tissue growthAnti vegf antibody
This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
Owner:GENENTECH INC
Anti-VEGF antibodies
Owner:GENENTECH INC
Anti-VEGF antibodies
ActiveUS20070020267A1Inhibit bindingSenses disorderImmunoglobulins against growth factorsAnti vegf antibodyBacteriophage
Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
Owner:GENENTECH INC
Fab library for the preparation of anti VEGF and anti rabies virus fabs
InactiveUS20060160184A1Maintain good propertiesOptimization mechanismAnimal cellsAntibody mimetics/scaffoldsProtein moleculesImmunoglobulin IgE
The present invention provides combinations of specific binding proteins, such as immunoglobulins, that are designed to be true combinations, essentially all components of the combination being functional and compatible with each other. The invention further provides a method for producing a composition comprising at least two different proteinaceous molecules comprising paired variable regions, the at least two proteinaceous molecules having different binding specificities, comprising paired variable regions, at least two proteinaceous molecules having different binding specificities, comprising contacting at least three different variable regions under conditions allowing for pairing of variable regions and harvesting essentially all proteinaceous molecules having binding specificities resulting from the pairing.
Owner:MERUS NV
Bispecific antibody to VEGF/PDGFR beta and application thereof
InactiveCN102250246AInhibition of newbornsGood tumor activityHybrid immunoglobulinsAntibody ingredientsSingle-Chain AntibodiesBispecific monoclonal antibody
The invention relates to a medicine of a bispecific monoclonal antibody, and especially to a medicine of a bispecific monoclonal antibody to human vascular endothelial growth factor (VEGF / VEGF-A) and platelet-derived growth factor receptor (PDGFR) for resistance to angiogenesis of tumor. The bispecific antibody to VEGF / PDGFR beta provided in the invention is characterized in that: a monoclonal antibody to VEGF is used as the base for the antibody and a single chain antibody to PDGFR beta is connected with the terminal of FC segment of the monoclonal antibody to VEGF to form the bispecific antibody to VEGF / PDGFR beta. The bispecific antibody related to in the invention is obtained by employing technical means like gene engineering and constructing antibody segments which identify VEGF and PDGFR beta in a same antibody molecule that can be specifically bound with the two antibody segments; the effect of the bispecific antibody on inhibiting angiogenesis of tumor issue is obviously superior to that of a single antibody to VEGF; and the bispecific antibody has good activity in resisting tumors.
Owner:CHANGZHOU ADAM BIOTECH
Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
InactiveUS20070224203A1Prolong survival timeProlong progression-free survivalImmunoglobulins against growth factorsAntibody ingredientsDiseaseTumor therapy
The present invention provides a method of treating a breast cancer disease in a patient who has failed prior treatment with an anti-VEGF antibody, comprising administering to the patient a therapeutically effective amount of an anti-HER2 antibody while continuing said anti-VEGF antibody therapy. The invention also provides corresponding pharmaceutical kits and pharmaceutical compositions.
Owner:F HOFFMANN LA ROCHE & CO AG
Anti-VEGF antibodies
ActiveUS7758859B2Senses disorderImmunoglobulins against growth factorsAnti vegf antibodyBacteriophage
Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
Owner:GENENTECH INC
Tumor therapy with an Anti-vegf antibody
InactiveUS20100285010A1Prevents and reduces metastasisImmunoglobulins against growth factorsAntibody ingredientsAfter treatmentAnti vegf antibody
Owner:FRIESS THOMAS +2
Methods and compositions for treating ocular disorders
InactiveUS20060293270A1Efficient ConcentrationEffective maintenanceGenetic material ingredientsGene therapyCompound (substance)Vascular endothelial growth factor
This invention relates to methods of treating ocular disease. The method of the invention is directed to the administration of an anti-vascular endothelial growth factor (anti-VEGF) compound to treat such disease.
Owner:EYETECH
Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab)
InactiveUS20070065449A1Great likelihoodLong median survivalBiocideGenetic material ingredientsAbnormal tissue growthLymphatic Spread
The present invention relates to a pharmaceutical cocktail, in particular, effective amounts of gemcitabine, in combination with effective amounts of docetaxel and angiogenesis inhibitor, especially a vascular endothelial growth factor (VEGF) inhibitor, such as bevacizumab for the treatment of cancer, in particular sarcoma, especially soft tissue sarcoma. Pharmaceutical compositions and methods of treating cancer, including sarcoma, especially soft tissue sarcoma (prolonging the patient's life, eliminating the tumor, improving the patient's quality of life, shrinking the tumor, prolonging survival and / or preventing the tumor's metastases) are additional aspects of the present invention.
Owner:STC UNM
Cancer treatements
ActiveUS20140178486A1Increase progression-free survival rateLive longerPowder deliveryOrganic active ingredientsNanoparticleCancer therapy
This document provides methods and materials related to treating cancer (e.g., skin cancer). For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle / antibody complexes (e.g., Abraxane® / anti-VEGF polypeptide antibody complexes) to treat cancer (e.g., skin cancer) are provided.
Owner:MAYO FOUND FOR MEDICAL EDUCATION & RES
Cancer treatments
ActiveUS20150246122A1Increase progression-free survival rateLive longerOrganic active ingredientsHeavy metal active ingredientsNanoparticleCancer therapy
This document provides methods and materials related to treating cancer (e.g., skin cancer). For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle / antibody complexes (e.g., ABRAXANE® / anti-VEGF polypeptide antibody complexes) to treat cancer (e.g., skin cancer) are provided.
Owner:MAYO FOUND FOR MEDICAL EDUCATION & RES
Humanized antibodies against vascular endothelial growth factor
InactiveUS7667004B2High binding affinityInhibit cell proliferationPeptide librariesAntibody mimetics/scaffoldsDiabetic retinopathyAntigen
Methods are provided for designing and selecting antibodies against human antigens with high affinity and specificity in silico and in vitro. In some particular embodiments, methods are provided for designing and selecting humanized or fully human antibodies against vascular endothelial growth factor (VEGF) with high affinity and specificity. In another aspect of the invention, monoclonal antibodies against VEGF are provided. In particular, humanized or human anti-VEGF monoclonal antibodies are provided with ability to bind to human VEGF with high affinity, inhibit VEGF-induced proliferation of endothelial cells in vitro and inhibit VEGF-induced angiogenesis in vivo. These antibodies and their derivative can be used in a wide variety of applications such as diagnosis, prevention, and treatment of diseases such as cancer, AMD, diabetic retinopathy, and other diseases derived from pathological angiogenesis.
Owner:ABMAXIS
Treating skin cancer
InactiveUS20100047234A1Improve survival rateImprove progressOrganic active ingredientsImmunoglobulins against growth factorsOncologyAnti vegf
Owner:MARKOVIC SVETOMIR N
Treating skin cancer
InactiveUS20140302017A1Improve survival rateImprove progressOrganic active ingredientsImmunoglobulins against growth factorsOncologyAnti vegf
Owner:MAYO FOUND FOR MEDICAL EDUCATION & RES
Cancer Treatments
ActiveUS20160235860A1Increase progression-free survival rateLive longerPowder deliveryHeavy metal active ingredientsNanoparticleOncology
Owner:MAYO FOUND FOR MEDICAL EDUCATION & RES
Combination therapy with thiocolchicine derivatives
The present invention provides combination therapy methods of treating a proliferative disease (such as cancer) comprising administering to an individual an effective amount of a colchicine or thiocolchicine dimer and an anti-VEGF antibody. The method may further comprise administering an effective amount of a taxane. The colchicine or thiocolchicine dimer and the taxane (such as paclitaxel) may be present in the form of nanoparticles, such as nanoparticles comprising the drug and a carrier protein such as albumin.
Owner:ABRAXIS BIOSCI LLC
Treating skin cancer
InactiveUS20120315273A1Improve survival rateImprove progressOrganic active ingredientsImmunoglobulins against growth factorsOncologyAnti vegf
Owner:MAYO FOUND FOR MEDICAL EDUCATION & RES
Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
ActiveUS8216575B2Reduce neovascularizationImprove acuitySenses disorderPeptide/protein ingredientsChimerin ProteinsEndothelial NOS
Described herein are novel soluble chimeric fusion proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including domain 4 of KDR. The claimed chimeric fusion proteins antagonize the endothelial cell proliferative and angiogenic activity of VEGF and are useful in the treatment of neovascularization-related disease.
Owner:CHENGDU KANGHONG BIOTECH
Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
InactiveUS20060134111A1Reduce riskAntipyreticAnalgesicsAngiogenesis AntagonistsAntiangiogenesis Therapy
The present application describes therapy with angiogenesis antagonists such as anti-VEGF antibodies. In particular, the application describes the use of such antagonists to treat autoimmune disease in a patient who has failed prior treatment such as treatment with DMARDs or TNFα-inhibitors.
Owner:GENENTECH INC
Method and apparatus for detecting and regulating vascular endothelial growth factor (VEGF) by forming a homeostatic loop employing a half-antibody biosensor
ActiveUS20100260679A1Maximize detection surface areaPeptide librariesBiological material analysisAbnormal tissue growthIn vivo
A biosensor for detection of vascular endothelial growth factor (VEGF) hybridization uses an array of parallel capacitors to detect electrochemical binding of circulating VEGF to immobilized anti-VEGF monoclonal half-antibodies (a-VEGF mhAb). Binding of a-VEGF mhAb modulates the threshold voltage of a circuit, changing the impedance of the circuit. An electrode coated with a p-Si substrate enhances the affinity between the VEGF molecules. A fluid cell delivers VEGF samples onto the active surface of the chip. An array of parallel capacitors arranged in an interdigitated pattern detects the VEGF in the fluid. The detector provides an accurately measured and quantifiable rate of change of the VEGF molecules in vivo, providing real time feedback which is used to measure response of the tumor to delivered chemotherapeutic agents and biological response modifiers (BRMs) for the purpose of determining tumor burden and efficacy of the chemotherapy as part of a homeostatic loop for chemotherapy.
Owner:SENSOR KINESIS
Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
InactiveUS20110064736A1Prolong survival timeProlong progression-free survivalImmunoglobulins against growth factorsAntibody ingredientsDiseaseFactor ii
The present invention provides a method of treating a breast cancer disease in a patient who has failed prior treatment with an anti-VEGF antibody, comprising administering to the patient a therapeutically effective amount of an anti-HER2 antibody while continuing said anti-VEGF antibody therapy. The invention also provides corresponding pharmaceutical kits and pharmaceutical compositions.
Owner:F HOFFMANN LA ROCHE & CO AG
Adjuvant cancer therapy
InactiveUS20100266589A1Prevent relapseReducing and preventing occurrenceImmunoglobulins against growth factorsAntibody ingredientsAdjuvantAnti vegf antibody
Owner:GENENTECH INC +1
5'-and 3'-capped aptamers and uses therefor
InactiveUS20050096290A1Reduce sensitivityImprove stabilitySenses disorderAntipyreticNeovascularizationAnti vegf
The invention provides compositions and methods for the treating disease using aptamers having 5′-5′ and 3′-3′ inverted nucleotide capped ends. In particular, the invention provides 5′-5′ and 3′-3′ capped anti-VEGF aptamers for the treatment of neovascularization-related diseases and disorders including age-related macular degeneration.
Owner:(OSI) EYETECH INC
VEGF-resistant and PD-1-resistant difunctional antibody and application thereof
ActiveCN105175545AHybrid immunoglobulinsImmunoglobulins against growth factorsMolecular ImmunologyT cell
The invention discloses a VEGF-resistant and PD-1-resistant difunctional antibody and application thereof, belonging to the technical field of molecular immunology. The VEGF-resistant and PD-1-resistant difunctional antibody contains a light chain an a heavy chain, wherein the light chain has an amino acid sequence as shown in SEQ ID NO.2, and the heavy chain has an amino acid sequence as shown in SEQ ID NO.4 or SEQ ID NO.6. Meanwhile, the invention provides a gene for encoding the difunctional antibody and the application of the difunctional antibody. The difunctional antibody provided by the invention can be combined with PD-1 and VEGF, has very high affinity, can be used for effectively simulating T cells to secrete IL2 and induce T cells to secrete IFN-gamma and can also be used for remarkably inhibiting the growth of tumor of a mouse so as to have a huge potential in application to preparation of anti-cancer drugs.
Owner:ANHUI RUBIOX VISION BIOTECH
VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
InactiveUS20080248033A1Reduce and prevent likelihoodPrevent relapseOrganic active ingredientsPeptide/protein ingredientsStaging tumorsStage tumor
Disclosed herein are methods of treating benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating a subject at risk of developing benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating or preventing recurrence of a tumor using an anti-VEGF-specific antagonist as well as use of VEGF-specific antagonists in neoadjuvant and adjuvant cancer therapy.
Owner:GENENTECH INC
Immunoconjugates with improved efficacy for the treatment of diseases
InactiveUS20070196274A1Improve therapeutic efficacyHigh detection sensitivityIn-vivo radioactive preparationsImmunoglobulins against animals/humansAntibody conjugateCD11a
The invention provides therapeutic or diagnostic antibodies with modified N— or C-terminal sequences that are enriched with lysine or tyrosine residues. These lysine or tyfosine residues can be used to couple radioisotopes, cytotoxic agents, or detectable labels. The increased stoichiometric ratios of these agents in the antibody conjugates lead to improved therapeutic efficacy or enhanced detection sensitivity. Non-limiting examples of antibodies suitable for the present invention include anti-CD22, anti-ErbB2, anti-VEGF, anti-EGFR, anti-VEGFR, anti-Her-3, anti-Her-4, anti-CEA, anti-CTLA-4, anti-CD4, anti-CD3, anti-CD20, anti-TNF-a, anti-CD11a, anti-Lewis Y antigen, anti-TrailR, anti-IL2R, anti-CD30, anti-CD146, anti-CD147, anti-alpha V integrin beta, anti-CD19, anti-GD2, anti-3H11, anti-EBV, anti-HIV, anti-HBV, anti-HCV, and other disease-specific antibodies.
Owner:WELSON PHARMA
Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
ActiveUS9695233B2Low viscosityHighly valuable propertySenses disorderImmunoglobulins against growth factorsVascular diseaseBispecific antibody
The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF / VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
Owner:ROCHE GLYCART AG
Personal Care Compositions and Methods for Their Use
InactiveUS20120014885A1Whitening skinReduce rednessCosmetic preparationsHair removalPersonal careDisease
The present invention provides peptides and supported peptides for treating various diseases and conditions. In particularly preferred embodiments, the present invention provides compositions and methods for personal care. In some embodiments, the present invention provides compositions for use in skin and / or hair care, as well as cosmetic compositions. In alternative particularly preferred embodiments, the present invention provides peptides and supported peptides for treating diseases of the skin, such as rosacea. In some particularly preferred embodiments, the supported peptides of the present invention are anti-VEGF peptides. In alternative particularly preferred embodiments, the anti-VEGF peptides are expressed on a scaffold protein. In some most preferred embodiments, the scaffold protein comprises BBI.
Owner:DANISCO US INC
Methods and compositions for treating macular degeneration
InactiveUS20050043220A1Reduce absorptionSenses disorderPeptide/protein ingredientsVascular endothelial growth factorAnti vegf
This invention relates to methods of treating age-related macular degeneration (AMD). In particular, this invention provides methods of treating all forms of wet, age-related macular degeneration. The method of the invention is directed to the administration of an anti-vascular endothelial growth factor (anti-VEGF) compound to treat wet AMD.
Owner:(OSI) EYETECH INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com